Journal of Cardiology Study & Research Category: Clinical Type: Audit

A Clinical Audit of Pulmonary Vein Isolation with Percutaneous Balloon Cryoablation in Refractory Atrial Fibrillation

Jing Voon Chow1*
1 Department of cardiology, Aberdeen Royal Infirmary, United kingdom

*Corresponding Author(s):
Jing Voon Chow
Department Of Cardiology, Aberdeen Royal Infirmary, United Kingdom
Email:jingvoon1212@gmail.com

Received Date: Sep 09, 2022
Accepted Date: Oct 06, 2022
Published Date: Oct 13, 2022

Objectives

Pulmonary vein isolations is the conventional rhythm-control therapy in treatment-resistant Atrial Fibrillation (AF). Cryoablation has emerged as a successful therapeutic option as it confers a beneficial effect on procedure time without compromising safety and efficacy due to its single-shot circumferential approach without conduction gap [1], in contrast to the conventional point-by-point application of radiofrequency energy [2].  This audit aimed to determine the clinical effectiveness of novel 28 mm cryoballoon ablation in Pulmonary Vein Isolations (PVIs) measured by freedom from AF from patients perspectives.

Methods

A total of 102 consecutive patients, aged 59.0 + 10.4 with paroxysmal (n=73) and persistent AF (n=29) at Aberdeen Royal Infirmarywho underwent de-novo PVIs between January 2012 and January 2019 were enrolled. All data was collected retrospectively via an anonymous catheter ablation database. Men and women constitute 76.5% and 23.5% of the study population respectively.

Results

Primary outcome is AF recurrence, defined as AF >30 seconds including initial blanking period of 3 months while secondary outcome is freedom from AF. Despite recurrence rate of 59/102 (57.8%), 12-month freedom from AF was reported in 52.9% patients and 24-month AF freedom in 69.6% patients after single cryoablation. 19 patients had repeat ablation with radiofrequency approach within 24 months after single cryoablation. AF persists in 12 patients. 88.2% procedures were complication-free (Table 1).

 Table 1: 24-month freedom from AF (n=90). Both segmented bar graphs are independent.

Conclusion

PVIs with percutaneous balloon cryoablation are an established therapy, attributed to its safety and clinical efficacy. A substantial proportion of patients experienced tremendous improvement in quality of life after single cryoablation and with further intervention during follow-up. This is justified by high incidence of 24-month freedom from AF.

References

Citation: Chow JV (2022) A Clinical Audit of Pulmonary Vein Isolation with Percutaneous Balloon Cryoablation in Refractory Atrial Fibrillation. J Cardiol Stud Res 7: 019.

Copyright: © 2022  Jing Voon Chow, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Herald Scholarly Open Access is a leading, internationally publishing house in the fields of Sciences. Our mission is to provide an access to knowledge globally.



© 2024, Copyrights Herald Scholarly Open Access. All Rights Reserved!